. 2021 Jan 18;110(4):479–506. doi: 10.1007/s00392-020-01799-3

Table 1.

Risk stratification in cardiac amyloidosis using biomarkers

	Amyloid subtype	NT-proBNP	Troponin T	Difference between free light chains kappa and lambda (= FLC-diff)	eGFR	Explanation of the score
Mayo Clinic Staging System	AL	≥ 1.800 pg/ml	≥ 0.025 ng/ml	≥ 18 mg/dl	–	One point per biomarker and thus a total score of 0 to 3 points, which allows the classification into stages I–IV. The mean survival is 94, 40, 14, and 6 months, depending on the stage
Staging according to Grogan et al.	ATTRwt	> 3.000 pg/ml	> 0.05 ng/ml	–	–	Classification into three stages with 4-year survival rates of 57, 42, and 18%, depending on whether none, one, or both biomarkers exceed the specified levels
Staging according to Gillmore et al.	ATTRwt ATTRv	> 3.000 ng/l	–	–	< 45 ml/min	Classification into three stages according to eGFR and NT-proBNP with mean life expectancies of 69 (both markers normal), 47 (one marker pathological), and 24 months (both markers pathological) in the three groups

Amyloid subtype

NT-proBNP

Troponin T

Difference between free light chains kappa and lambda (= FLC-diff)

eGFR

Explanation of the score

Mayo Clinic Staging System

≥ 1.800 pg/ml

≥ 0.025 ng/ml

≥ 18 mg/dl

–

One point per biomarker and thus a total score of 0 to 3 points, which allows the classification into stages I–IV. The mean survival is 94, 40, 14, and 6 months, depending on the stage

Staging according to Grogan et al.

ATTRwt

> 3.000 pg/ml

> 0.05 ng/ml

–

Classification into three stages with 4-year survival rates of 57, 42, and 18%, depending on whether none, one, or both biomarkers exceed the specified levels

Staging according to Gillmore et al.

ATTRwt

ATTRv

> 3.000 ng/l

–

< 45 ml/min

Classification into three stages according to eGFR and NT-proBNP with mean life expectancies of 69 (both markers normal), 47 (one marker pathological), and 24 months (both markers pathological) in the three groups